MENOPAUSAL SYMPTOMS AND OSTEOPOROSIS PROPHYLAXIS 1.5 MG DAILY CONTINUOUSLY (WITH CYCLICAL PROGESTOGEN FOR 10-13 DAYS OF EACH CYCLE IN WOMEN WITH INTACT UTERUS); UP TO 3 MG DAILY (IN SINGLE OR DIVIDED DOSES) FOR VASOMOTOR SYMPTOMS AND MENOPAUSAL VAGINITIS.
FOR TREATMENT OF FEMALE HYPOESTROGENISM DUE TO HYPOGONADISM, CASTRATION, OR PRIMARY OVARIAN FAILURE. USUAL DOSAGE RANGES: FEMALE HYPOGONADISM A DAILY DOSE OF ONE OGEN 1.25 (1.5 MG ESTROPIPATE) TABLET TO THREE OGEN 2.5 (3 MG ESTROPIPATE) TABLETS MAY BE GIVEN FOR THE FIRST THREE WEEKS OF A THEORETICAL CYCLE, FOLLOWED BY A REST PERIOD OF EIGHT TO TEN DAYS. THE LOWEST DOSE THAT WILL CONTROL SYMPTOMS SHOULD BE CHOSEN. IF BLEEDING DOES NOT OCCUR BY THE END OF THIS PERIOD, THE SAME DOSAGE SCHEDULE IS REPEATED. THE NUMBER OF COURSES OF ESTROGEN THERAPY NECESSARY TO PRODUCE BLEEDING MAY VARY DEPENDING ON THE RESPONSIVENESS OF THE ENDOMETRIUM. IF SATISFACTORY WITHDRAWAL BLEEDING DOES NOT OCCUR, AN ORAL PROGESTOGEN MAY BE GIVEN IN ADDITION TO ESTROGEN DURING THE THIRD WEEK OF THE CYCLE.
FEMALE CASTRATION OR PRIMARY OVARIAN FAILUREβA DAILY DOSE OF ONE OGEN 1.25 (1.5 MG ESTROPIPATE) TABLET TO THREE OGEN 2.5 (3 MG ESTROPIPATE) TABLETS MAY BE GIVEN FOR THE FIRST THREE WEEKS OF A THEORETICAL CYCLE, FOLLOWED BY A REST PERIOD OF EIGHT TO TEN DAYS. ADJUST DOSAGE UPWARD OR DOWNWARD ACCORDING TO SEVERITY OF SYMPTOMS AND RESPONSE OF THE PATIENT. FOR MAINTENANCE, ADJUST DOSAGE TO LOWEST LEVEL THAT WILL PROVIDE EFFECTIVE CONTROL.
FOR PREVENTION OF OSTEOPOROSIS. A DAILY DOSE OF ONE OGEN .625 (0.75 MG ESTROPIPATE) TABLET FOR 25 DAYS OF A 31-DAY CYCLE PER MONTH.